AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 767091 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping and preparing the denture-bearing base and its mucosal side
Number of subjects: 0
Study 767091 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical and hygienic measures
Number of subjects: 0
Study 31513474 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative feedback
Number of subjects: 130
Study 31513474 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 130
Study 31583921 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone combined with calcium
Number of subjects: 160
Study 31583921 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone
Number of subjects: 160
Study 31583921 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 160
Study 31583921 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 160
Study 30589965 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan (20 mg daily)
Number of subjects: 32
Study 30589965 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg daily)
Number of subjects: 32
Study 28231950 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG3-β1AR-AAbs group
Number of subjects: 353
Study 28231950 — intervention group
Group type: COMPARATOR
Intervention: Non-IgG3 group
Number of subjects: 353
Study 25773009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose multivitamin and mineral supplement (1× RDI for 30 days, then 2× RDI for 30 days)
Number of subjects: 66
Study 23447043 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of indapamide
Number of subjects: 20
Study 23447043 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of indapamide
Number of subjects: 20
Study 20872082 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse Drug Events (ADEs)
Number of subjects: 3459
Study 20872082 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Errors
Number of subjects: 3459
Study 20872082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatal ADEs
Number of subjects: 3459
Study 20872082 — intervention group
Group type: EXPERIMENTAL
Intervention: Life-threatening ADEs
Number of subjects: 3459
Study 20872082 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious ADEs
Number of subjects: 3459
Study 20872082 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate per admission
Number of subjects: 3459
Study 19576324 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT (1 g for 4 weeks advanced to 2 g for 12 weeks)
Number of subjects: 1455
Study 19576324 — intervention group
Group type: EXPERIMENTAL
Intervention: ERN/LRPT
Number of subjects: 1455
Study 19576324 — intervention group
Group type: COMPARATOR
Intervention: N-ER (0.5 g for 4 weeks titrated in 0.5-g increments every 4 weeks to 2 g for the final 4 weeks)
Number of subjects: 1455
Study 19576324 — intervention group
Group type: COMPARATOR
Intervention: N-ER
Number of subjects: 1455
Study 17054812 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.42 with balanced crystalloid solution (Group A)
Number of subjects: 30
Study 17054812 — intervention group
Group type: COMPARATOR
Intervention: Conventional HES 130/0.42 plus unbalanced crystalloid (saline solution) (Group B)
Number of subjects: 30
Study 15129747 — intervention group
Group type: EXPERIMENTAL
Intervention: One-dimensional stimulus-response mapping
Number of subjects: 0
Study 15129747 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional stimulus-response mapping
Number of subjects: 0
Study 11838060 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation group (20 patients) - implanted with compound artificial bone of HA‐Bone cement
Number of subjects: 40
Study 11838060 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 40
Study 11838060 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation group
Number of subjects: 40
Study 9565283 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetized water oral irrigator
Number of subjects: 29
Study 7798544 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo-controlled oral food challenges with cow's milk, hen's egg, cow's milk and hen's egg, or placebo
Number of subjects: 25
Study 7798544 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil cationic protein measurement
Number of subjects: 25
Study 3292997 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine
Number of subjects: 110
Study 3292997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 30424796 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guidance
Number of subjects: 1546
Study 30424796 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (without PCT guidance)
Number of subjects: 1546
Study 27052516 — intervention group
Group type: EXPERIMENTAL
Intervention: Padua prediction score (PPS)
Number of subjects: 628
Study 27052516 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgment
Number of subjects: 628
Study 24723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia
Number of subjects: 1685
Study 24723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar depression
Number of subjects: 1685
Study 24723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder
Number of subjects: 1685
Study 24723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar depression
Number of subjects: 1685
Study 24723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar mania
Number of subjects: 1685
Study 24723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall rate of TSH levels above or below normal range
Number of subjects: 1685
Study 24723220 — intervention group
Group type: EXPERIMENTAL
Intervention: Age correlation with TSH levels
Number of subjects: 1685
Study 24376546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesico Amniotic Shunt (VAS)
Number of subjects: 0
Study 24376546 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study 20842069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin for 20 days
Number of subjects: 131
Study 20842069 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation cephalosporin for 30 days
Number of subjects: 131
Study 20842069 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (Clindamycin and First-generation cephalosporin)
Number of subjects: 131
Study 18469566 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy (injections of a solution made from 1 part 5% sodium morrhuate, 1.5 parts 50% dextrose, 0.5 parts 4% lidocaine, 0.5 parts 0.5% sensorcaine and 3.5 parts normal saline)
Number of subjects: 24
Study 18469566 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Number of subjects: 24
Study 18469566 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline injections)
Number of subjects: 24
Study 15842136 — intervention group
Group type: EXPERIMENTAL
Intervention: Weichangshu (WCS)
Number of subjects: 96
Study 15842136 — intervention group
Group type: COMPARATOR
Intervention: Mosapride Citrate tablet
Number of subjects: 96
Study 15842136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (WCS and Mosapride)
Number of subjects: 96
Study 12589712 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 87
Study 12589712 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with concomitant chemotherapy
Number of subjects: 87
Study 10496460 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute chocolate ingestion
Number of subjects: 0
Study 7481231 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative breast surgery with adjuvant radiotherapy
Number of subjects: 0
Study 7481231 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy
Number of subjects: 0
Study 1683249 — intervention group
Group type: EXPERIMENTAL
Intervention: Abanoquil (0.4 micrograms kg‐1 i.v.)
Number of subjects: 2
Study 1683249 — intervention group
Group type: EXPERIMENTAL
Intervention: Abanoquil (0.5 micrograms kg‐1 i.v.)
Number of subjects: 2
Study 1683249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 6257815 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B (TP)
Number of subjects: 68
Study 6257815 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfacetamide-polymyxin B (TSP)
Number of subjects: 68
Study 31765731 — intervention group
Group type: EXPERIMENTAL
Intervention: NFB + tDCS (10 min of tDCS before each NFB session, 2 days per week, 10 sessions of 30 min)
Number of subjects: 16
Study 31765731 — intervention group
Group type: COMPARATOR
Intervention: NFB (2 days per week, 10 sessions of 30 min)
Number of subjects: 16
Study 31294924 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate + tipepidine
Number of subjects: 53
Study 31294924 — intervention group
Group type: COMPARATOR
Intervention: methylphenidate + placebo
Number of subjects: 53
Study 28625164 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly teleconsultations with a specialist palliative care consultation team (SPCT) for 12 weeks
Number of subjects: 74
Study 28625164 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 74
Study 27468140 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 69
Study 24392964 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted laterally positioned flap (LALPF)
Number of subjects: 32
Study 24392964 — intervention group
Group type: COMPARATOR
Intervention: Laterally positioned flap (LPF)
Number of subjects: 32
Study 22105893 — intervention group
Group type: COMPARATOR
Intervention: External Humidifier (EH)
Number of subjects: 53
Study 22105893 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchanger (HME)
Number of subjects: 53
Study 20044678 — intervention group
Group type: EXPERIMENTAL
Intervention: Drains
Number of subjects: 78
Study 20044678 — intervention group
Group type: COMPARATOR
Intervention: No drains
Number of subjects: 78
Study 20044678 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 18753862 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r 290/115 mg/m twice-daily
Number of subjects: 115
Study 18753862 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r 375/150 mg/m twice-daily
Number of subjects: 115
Study 18753862 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV/r (both doses)
Number of subjects: 115
Study 15883444 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified milk (Ca milk)
Number of subjects: 606
Study 15883444 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D-fortified milk (CaD milk)
Number of subjects: 606
Study 15883444 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 606
Study 12767656 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 389
Study 12767656 — intervention group
Group type: COMPARATOR
Intervention: Coronary Artery Bypass Graft (CABG)
Number of subjects: 389
Study 10364784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-glucose-xylitol mixture (FGX)
Number of subjects: 119
Study 10364784 — intervention group
Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 119
Study 8678570 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (7 mg/kg per day) for 3 weeks
Number of subjects: 140
Study 8678570 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 140
Study 8678570 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Itraconazole and Placebo)
Number of subjects: 140
Study 8351043 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable antiplaque preparation containing chlorhexidine, fluoride, and xylitol
Number of subjects: 0
Study 3528964 — intervention group
Group type: EXPERIMENTAL
Intervention: MP therapy
Number of subjects: 257
Study 3528964 — intervention group
Group type: EXPERIMENTAL
Intervention: VCMP therapy
Number of subjects: 257
Study 3528964 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 257
Study 3528964 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide therapy
Number of subjects: 257
Study 3528964 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug therapy (VBAMDex)
Number of subjects: 257
Study 30056412 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy simulator
Number of subjects: 80
Study 30056412 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 27154574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnic conditions
Number of subjects: 40
Study 27154574 — intervention group
Group type: COMPARATOR
Intervention: Hypercapnic conditions
Number of subjects: 40
Study 23838692 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-family group therapy from MFEC
Number of subjects: 50
Study 23838692 — intervention group
Group type: COMPARATOR
Intervention: Control group (access to a range of interventions, but not multi-family therapy)
Number of subjects: 50
Study 24133059 — intervention group
Group type: EXPERIMENTAL
Intervention: Garcinia cambogia extract (2.4 g, 800 mg 3×/day, 50% HCA)
Number of subjects: 43
Study 24133059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 22493101 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC) - three 5‐min cycles of upper limb ischaemia and reperfusion after anaesthesia induction.
Number of subjects: 80
Study 22493101 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (no specific details provided).
Number of subjects: 80
Study 19283590 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pressure massage
Number of subjects: 20
Study 19283590 — intervention group
Group type: COMPARATOR
Intervention: Light pressure massage
Number of subjects: 20
Study 19070025 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ferrous sulfate 5 times/week
Number of subjects: 94
Study 19070025 — intervention group
Group type: COMPARATOR
Intervention: Placebo 5 times/week
Number of subjects: 94
Study 16335907 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET group, n = 48)
Number of subjects: 96
Study 16335907 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (ROSI group, n = 48)
Number of subjects: 96
Study 16335907 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 96
Study 11995344 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion at a rate of 0.01 microgram.kg‐1.min‐1 during and after the operation (30‐40 hrs)
Number of subjects: 20
Study 11995344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PGE1 infusion)
Number of subjects: 20
Study 9701620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin C intake (100 mg increment)
Number of subjects: 775
Study 9701620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin C intake (100 mg increment) with higher calcium intake (>500 mg/day)
Number of subjects: 775
Study 9701620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin C intake (100 mg increment) with lower calcium intake (<=500 mg/day)
Number of subjects: 775
Study 8904263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular morphine premedication (0.14 mg/kg) with epidural morphine (4 mg immediately after operation and 3 mg ten hours later)
Number of subjects: 41
Study 8904263 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (4 mg immediately after operation and 3 mg ten hours later)
Number of subjects: 41
Study 8904263 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine premedication (0.14 mg/kg) with epidural saline (saline control)
Number of subjects: 41
Study 8904263 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (saline control)
Number of subjects: 41
Study 8904263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular morphine premedication (0.14 mg/kg)
Number of subjects: 41
Study 8904263 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 41
Study 1898841 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.3‐0.4 mg orally)
Number of subjects: 12
Study 1898841 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.21 mg/kg intramuscularly)
Number of subjects: 12
Study 1898841 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine plus Morphine (0.3‐0.4 mg orally and 0.21 mg/kg intramuscularly)
Number of subjects: 12
Study 1898841 — intervention group
Group type: COMPARATOR
Intervention: Clonidine alone
Number of subjects: 12
Study 1898841 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 12
Study 1898841 — intervention group
Group type: COMPARATOR
Intervention: Clonidine plus Morphine
Number of subjects: 12
Study 1898841 — intervention group
Group type: COMPARATOR
Intervention: All three drug groups
Number of subjects: 12
Study 6682668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (2 mg daily for 6 months)
Number of subjects: 24
Study 6682668 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (1050 mg daily for 6 months)
Number of subjects: 24
Study 30411601 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical relaxing music
Number of subjects: 32
Study 30411601 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected relaxing music
Number of subjects: 32
Study 30411601 — intervention group
Group type: COMPARATOR
Intervention: Control (no music)
Number of subjects: 32
Study 30152603 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPPS + treatment as usual
Number of subjects: 193
Study 30152603 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual alone
Number of subjects: 193
Study 27492324 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium and/or vitamin E
Number of subjects: 0
Study 27492324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25489101 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (0.5 mg per day orally for 3 consecutive days)
Number of subjects: 22
Study 25489101 — intervention group
Group type: COMPARATOR
Intervention: Standard management alone (Control)
Number of subjects: 22
Study 21415283 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 99
Study 19171951 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine case management
Number of subjects: 0
Study 19171951 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17224709 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 0
Study 17224709 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/d
Number of subjects: 0
Study 17224709 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/d
Number of subjects: 0
Study 17224709 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine
Number of subjects: 0
Study 17224709 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 0
Study 14724397 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12242928 — intervention group
Group type: EXPERIMENTAL
Intervention: IVRA technique with the application of a simple forearm tourniquet
Number of subjects: 20
Study 12242928 — intervention group
Group type: COMPARATOR
Intervention: Standard IVRA technique
Number of subjects: 20
Study 9657442 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin administered subcutaneously once daily at a dose of 180 anti-factor Xa IU.kg(‐1) for 6 to 10 days
Number of subjects: 36
Study 7832822 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hypertonic saline 7 ml kg‐1
Number of subjects: 33
Study 7832822 — intervention group
Group type: COMPARATOR
Intervention: 0.9% isotonic saline 7 ml kg‐1
Number of subjects: 33
Study 2059591 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (10 mg)
Number of subjects: 30
Study 2059591 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg)
Number of subjects: 30
Study 6955678 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride 250 mg qid for 10 days
Number of subjects: 59
Study 6955678 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride 100 mg bid for 10 days
Number of subjects: 59
Study 30999056 — intervention group
Group type: EXPERIMENTAL
Intervention: injectable phloroglucinol
Number of subjects: 9
Study 30999056 — intervention group
Group type: COMPARATOR
Intervention: stain remover (active control)
Number of subjects: 9
Study 30999056 — intervention group
Group type: COMPARATOR
Intervention: water (placebo)
Number of subjects: 9
Study 30094818 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERACT program implementation
Number of subjects: 264
Study 30094818 — intervention group
Group type: COMPARATOR
Intervention: Low or moderate INTERACT use
Number of subjects: 264
Study 26806917 — intervention group
Group type: COMPARATOR
Intervention: Heart transplant (HT)
Number of subjects: 31
Study 24801148 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose drug dispensing (MDD)
Number of subjects: 200
Study 24801148 — intervention group
Group type: COMPARATOR
Intervention: Ordinary prescriptions (no MDD)
Number of subjects: 200
Study 22956303 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Parent Training (BPT)
Number of subjects: 216
Study 22956303 — intervention group
Group type: COMPARATOR
Intervention: Regular services (comparison group)
Number of subjects: 216
Study 19647623 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative glutamine supplementation (0.3 g . kg(‐1) x d(‐1) for 5 days)
Number of subjects: 34
Study 19647623 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glutamine supplementation)
Number of subjects: 34
Study 17721395 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (100, 200, 400, and 600 mg twice daily)
Number of subjects: 198
Study 17721395 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (600 mg/d)
Number of subjects: 198
Study 15746636 — intervention group
Group type: EXPERIMENTAL
Intervention: Redon drain (4 drains)
Number of subjects: 30
Study 15746636 — intervention group
Group type: COMPARATOR
Intervention: Conventional drain (2 drains)
Number of subjects: 30
Study 15746636 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 12518847 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) treatment
Number of subjects: 0